Jazz Pharmaceuticals plc

NASDAQ: JAZZ
$123.61
+$4.53 (+3.8%)
Closing Price on November 8, 2024

JAZZ Stock Chart and Intraday Price

JAZZ Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IE
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 7,482.43M USD
Shares Outstanding 62,957,000
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and marketing innovative medicines to meet significant unmet medical needs. With a diverse portfolio, Jazz Pharmaceuticals offers treatments for narcolepsy, epilepsy, cancer, and acute leukemia among other serious conditions. Their products include Xywav, Xyrem, Epidiolex, and Zepzelca, addressing issues from sleep disorders to severe forms of epilepsy and cancer. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is committed to improving patients' lives through science, with ongoing research in neurological disorders and oncology.

JAZZ Articles

Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.  The billionaire is a value investor in the vein of...
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk,...
Wednesday's top analyst upgrades and downgrades included AutoZone, EOG Resources, Etsy, Huntsman, Luminar Technologies, Nike, Norwegian Cruise Line, PayPal, Pioneer Natural Resources, Western Digital...
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF...
Wednesday’s additional top analyst upgrades and downgrades included AbbVie, Bristol-Myers, JetBlue, and more.
Monday's top analyst upgrades and downgrades included Adobe, Anheuser-Busch, Baker Hughes, Chevron, Eli Lilly, Halliburton, Home Depot, Intuit, Microsoft, Robinhood Markets, Shopify, Sirius XM,...
Tuesday's top analyst upgrades and downgrades included Albertsons, Charles Schwab, Colgate-Palmolive, CyberArk Software, Deckers Outdoor, Dow, Lordstown Motors, Nike, Procter & Gamble and Tesla.
Thursday's top analyst upgrades and downgrades included Amgen, Biogen, Commscope, Lockheed Martin, Northrop Grumman, ONEOK, Plug Power and Roku.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Abercrombie & Fitch, Pfizer and Teva Pharmaceutical.
These four Jefferies growth stock picks for more aggressive investors all have significant catalysts to drive growth the rest of 2021 and beyond. Two of them are red-hot companies cashing in on...
The Friday afternoon analyst calls were focused on Biogen, Fortinet, Pinterest, Snap and more.
London-based Jazz Pharmaceuticals has agreed to pay $7.2 billion to acquire GW Pharmaceuticals, a maker of drugs derived from cannabis plants.
Wednesday's top analyst upgrades and downgrades included Chipotle Mexican Grill, Etsy, Exxon Mobil, General Electric, Jazz Pharmaceuticals, Microsoft, Nikola, Palo Alto Networks, Pfizer and Twitter.
BofA Securities has released its top ideas for the rest of 2021. Here are eight top long ideas and two potential shorts for more aggressive investors.